Skip to main content

Neurology Rett Center Fast-Tracks Personalized Treatment for Twins with Ultra Rare Genetic Disorder

September 26, 2024
In May 2022, Yael Shiloh-Malawsky, MD, a neurologist at the UNC School of Medicine, met two new patients combatting a rare and fatal neurodegenerative disorder called Batten disease. With help from UNC, the twin girls were able to get personalized treatment from bench to bedside in record time.

Chris E. Hilliard Appointed as NCTU Director

July 25, 2024
The Department of Neurology is pleased to welcome Christopher Hilliard, BS, CCRC to the position of NCTU Director. Chris will join the department of Neurology with 10 years of experience in clinical research trials, training, mentoring, and leading large research teams. In his previous role, Chris served as the Assistant Director of Clinical Operations...

Dr. James Howard has a hand in ME&MGopen clinical study

September 27, 2023
Press Release Courtesy of EIN Presswire and Ad Scientiam. The ME&MGopen study has already recruited 165 patients in the USA and 11 in Canada. This innovative program is supported by Alexion, AstraZeneca Rare Disease. PARIS, FRANCE, September 21, 2023 /EINPresswire.com/ — Generalized Myasthenia Gravis (gMG) is a chronic autoimmune neuromuscular...

Non-invasive brain stimulation for Parkinson’s non-motor symptoms

May 12, 2023
Are you interested in advancing treatments in Parkinson’s disease? Did you know that the non-motor symptoms of Parkinson’s disease are often very disabling and can lead to poor outcomes with the disease? If you have Parkinson’s disease, you may be eligible to take part in a research study to learn...

Zynerba 033

May 12, 2023
This is a randomized, double-blind, placebo-controlled, multiple-center study, to assess the efficacy and safety of CBD administered as ZYN002, a transdermal gel, for the treatment of children and adolescent patients with FXS. Status: Not currently enrolling

Phase 2 Study of ALXN2050 in Generalized Myasthenia Gravis

May 10, 2023
A study is being conducted to understand the effectiveness of ALXN2050 compared with placebo in the treatment of generalized MG (gMG) based on improvement in the Myasthenia Gravis Activities of Daily Living (MG-ADL) total score. Status: Open

Parkinson’s Disease Genetic Registry

May 10, 2023
This is a genetic registry study aimed at developing a central location to store Parkinson’s Disease genetic data for future research use. Status: Open

Circadian rhythm in rock climbing performance

April 19, 2023
Circadian rhythm is well known to affect various aspects of sports performance; however, the sport-specific effects in rock climbing are not well studied. We aim to evaluate diurnal changes in maximum finger strength, finger endurance, and power in rock climbers. Status: Not currently enrolling

IMVT Batoclimab Efficacy and Safety

April 19, 2023
This study aims to test the safety and effectiveness of batoclimab in treating patients with Myasthenia Gravis. Status: Open

Phase 3 study results show positive data in treatment of myasthenia gravis with zilucoplan

February 14, 2022
James F. Howard Jr., MD, professor in the UNC Department of Neurology, was lead investigator in UCB's RAISE trial to evaluate zilucoplan as a treatment for generalized myasthenia gravis in adults.